Our results establish MTX as a macrophage reprogramming drug and evidence that its therapeutic benefits go beyond limiting tumor cell proliferation, suggesting that GSK3β might be the final target of the antitumor strategies, aiming at CSF1R or PI3Kγ. This evidence concerns the gene GSK3B and neoplasm.